Related references
Note: Only part of the references are listed.Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
Yao Dai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Neru Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Treatment of metastatic renal cell carcinoma
Maxine Sun et al.
NATURE REVIEWS UROLOGY (2010)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2009)
Targeting the Met signaling pathway in renal cancer
Alessio Giubellino et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells
Harriet M. Kluger et al.
LABORATORY INVESTIGATION (2008)
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma
Hironori Betsunoh et al.
CANCER SCIENCE (2007)
c-Met is a potentially new therapeutic target for treatment of human melanoma
Neelu Puri et al.
CLINICAL CANCER RESEARCH (2007)
Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm?
Th. Van der Kwast et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Renal cancer cells lacking hypoxia inducible factor (HIF)-1 alpha expression maintain vascular endothelial growth factor expression through HIF-2 alpha
Toshiaki Shinojima et al.
CARCINOGENESIS (2007)
Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma
Yasuyoshi Miyata et al.
CLINICAL CANCER RESEARCH (2006)
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma
N Nakaigawa et al.
CANCER RESEARCH (2006)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Automated subcellular localization and quantification of protein expression in tissue microarrays
RL Camp et al.
NATURE MEDICINE (2002)
Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas
RR Oh et al.
APMIS (2002)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
GHJ Mickisch et al.
LANCET (2001)
Share Paper
